| YORKVILLE |
YORKVILLE |
92%
|
On July 29, 2025, the Company entered into a PPA with Yorkville, pursuant to which the Company may request pre-paid advances of up to $ 6,000 from Yorkville over a 12-month period |
| FUNICULAR-FUNDS-LP |
FUNICULAR-FUNDS-LP |
90%
|
Rein Therapeutics, Inc. issued and sold to Funicular, in a private placement, an unsecured promissory note |
| MEDICAL-UNIVERSITY-OF-SOUTH-CAROLINA-FOUNDATION- |
MEDICAL-UNIVERSITY-OF-SOUTH-CAROLINA-FOUNDATION- |
90%
|
Amended and Restated License Agreement, effective as of September 1, 2018, by and between Lung Therapeutics, Inc. and Medical University of South Carolina Foundation for Research Development |
| MUSC-AGREEMENT |
MUSC-AGREEMENT |
90%
|
In consideration of the MUSC Agreement, we agreed to pay a non-refundable license fee, patent expenses, milestone fees upon certain development, regulatory and commercial milestone events, sublicense… |
| TAIHO-PHARMACEUTICAL-CO-LTD |
TAIHO-PHARMACEUTICAL-CO-LTD |
90%
|
Exclusive License Agreement, dated as of November 12, 2020, by and between Lung Therapeutics, Inc. and Taiho Pharmaceutical Co. Ltd. |
| THE-UNIVERSITY-OF-TEXAS-SYSTEM |
THE-UNIVERSITY-OF-TEXAS-SYSTEM |
90%
|
Amended and Restated Patent and Technology License Agreement, effective as of December 19, 2013, by and between Lung Therapeutics, Inc. and the Board of Regents of The University of Texas System, on … |
| UNIVERSITY-OF-TEXAS-AT-AUSTIN |
UNIVERSITY-OF-TEXAS-AT-AUSTIN |
90%
|
Patent License Agreement, effective as of May 21, 2015, by and between Lung Therapeutics, Inc. and the University of Texas at Austin, on behalf of The University of Texas System |
| VIVARTA-THERAPEUTICS-L-L-C |
VIVARTA-THERAPEUTICS-L-L-C |
90%
|
License Agreement, effective as of March 8, 2018, by and between Lung Therapeutics, Inc. and Vivarta Therapeutics, L.L.C. |
| VIVARTA-THERAPEUTICS-LLC |
VIVARTA-THERAPEUTICS-LLC |
90%
|
In consideration of the Vivarta Agreement, we also agreed to pay patent expenses, milestone fees upon certain development and regulatory milestone events, sublicense fees, assignment fees and low sin… |
| CELG-RI |
CELG-RI |
72%
|
development stage. Manufacturing We do not own or operate manufacturing facilities for the production of any of our product candidates, nor do we have plans to develop our own manufacturing operation… |
| CELG-RI |
CELG-RI |
72%
|
Reciprocal relationship from CELG-RI graph: Reciprocal relationship from RNTX graph: development stage. Manufacturing We do not own or operate manufacturing facilities for the production of any of ou… |
| GILD |
Gilead Sciences, Inc. |
72%
|
Reciprocal relationship from GILD graph: Reciprocal relationship from RNTX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from RNTX graph: development stage. Manufacturing We… |
| GILD |
Gilead Sciences, Inc. |
72%
|
development stage. Manufacturing We do not own or operate manufacturing facilities for the production of any of our product candidates, nor do we have plans to develop our own manufacturing operation… |
| NVSEF |
Novartis AG |
72%
|
development stage. Manufacturing We do not own or operate manufacturing facilities for the production of any of our product candidates, nor do we have plans to develop our own manufacturing operation… |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from RNTX graph: development stage. Manufacturing We do not own or operate manufacturing facilities for the production of any of our … |
| PRTC |
PureTech Health plc |
72%
|
Reciprocal relationship from PRTC graph: Reciprocal relationship from RNTX graph: Reciprocal relationship from PRTC graph: Reciprocal relationship from RNTX graph: Reciprocal relationship from PRTC g… |
| PRTCY |
PRTCY |
72%
|
Reciprocal relationship from PRTCY graph: Reciprocal relationship from RNTX graph: Reciprocal relationship from PRTCY graph: Reciprocal relationship from RNTX graph: development stage. Manufacturing … |
| PRTCY |
PRTCY |
72%
|
development stage. Manufacturing We do not own or operate manufacturing facilities for the production of any of our product candidates, nor do we have plans to develop our own manufacturing operation… |
| VCRE |
VCRE |
72%
|
Reciprocal relationship from VCRE graph: Reciprocal relationship from RNTX graph: development stage. Manufacturing We do not own or operate manufacturing facilities for the production of any of our p… |
| VCRE |
VCRE |
72%
|
development stage. Manufacturing We do not own or operate manufacturing facilities for the production of any of our product candidates, nor do we have plans to develop our own manufacturing operation… |
